{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-003940","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.016640+00:00","generated_at":"2026-06-19T02:48:06.575963+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Intellia Q4 net loss $113.4M, cash $1.3B; NTLA-2002 Phase 2 started, NTLA-2001 pivotal plan on track","bullets":["Q4 2022 net loss $113.4M vs $81.2M YoY; R&D expenses rose to $100.0M from $71.2M.","Cash, equivalents and marketable securities $1.3B as of Dec 31, 2022, up from $1.1B.","Initiated global Phase 2 study of NTLA-2002 for HAE; submitted IND to FDA for U.S. enrollment.","Plan to submit IND for NTLA-2001 in ATTR-CM in mid-2023; global pivotal trial expected by year-end 2023.","IND-enabling activities for NTLA-3001 (AATD lung) with filing planned in 2H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-003940","json":"https://secwatch.observer/filing/0000950170-23-003940.json","markdown":"https://secwatch.observer/filing/0000950170-23-003940.md","text":"https://secwatch.observer/filing/0000950170-23-003940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000095017023003940/0000950170-23-003940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000095017023003940/ntla-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:48:06.575963+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33c90d0387cc1fb2c7580c418aedeedd4a370949","claim":"Intellia Therapeutics, Inc. reported financial results for quarter and year ended December 31, 2022.","evidence_excerpt":"On February 23, 2023, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017023003940/0000950170-23-003940-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}